Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old | Zendy

Anthony Enimil | Zendy; Sampson Antwi | Zendy; Hongmei Yang | Zendy; Albert Dompreh | Zendy; Wael A. Alghamdi | Zendy; Fizza S. Gillani | Zendy; Antoinette Orstin | Zendy; Dennis Bosomtwe | Zendy; Theresa Opoku | Zendy; Jennifer Norman | Zendy; Lubbe Wiesner | Zendy; Taimour Langaee | Zendy; Charles A. Peloquin | Zendy; Michael H. Court | Zendy; David J. Greenblatt | Zendy; Awewura Kwara | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old

Author(s) -

Anthony Enimil,

Sampson Antwi,

Hongmei Yang,

Albert Dompreh,

Wael A. Alghamdi,

Fizza S. Gillani,

Antoinette Orstin,

Dennis Bosomtwe,

Theresa Opoku,

Jennifer Norman,

Lubbe Wiesner,

Taimour Langaee,

Charles A. Peloquin,

Michael H. Court,

David J. Greenblatt,

Awewura Kwara

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00839-19

Subject(s) - nevirapine , coinfection , medicine , tuberculosis , pharmacokinetics , antiretroviral therapy , pediatrics , human immunodeficiency virus (hiv) , virology , viral load , pathology

Nevirapine-based antiretroviral therapy (ART) is one of the limited options in HIV-infected children younger than 3 years old (young children) with tuberculosis (TB) coinfection. To date, there are insufficient data to recommend nevirapine-based therapy during first-line antituberculosis (anti-TB) therapy in young children. We compared nevirapine pharmacokinetics (PK) in HIV-infected young children with and without TB coinfection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research